Long-Term Control of Metastatic Renal Cell Carcinoma Using Pazopanib.
Metastatic renal cell carcinoma
Nivolumab
Pazopanib
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
18
06
2019
accepted:
20
06
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
21
8
2019
Statut:
epublish
Résumé
COMPARZ study revealed no marked differences in terms of the progression free survival and overall survival between sunitinib and pazopanib treatment. Regarding the quality of life and early tumor shrinkage, pazopanib showed more favorable results than sunitinib treatment. A 70-year-old man underwent right nephrectomy in 2015. In 2017, iliac bone metastasis was found and consequently lung metastasis was developed. Pazopanib (200 mg × 4 tablets) was introduced. He showed no abnormal liver function markers during pazopanib treatment for more than two years and the size and number of lung metastases decreased. We herein report a case of successful control of metastatic renal cell carcinoma for more than two years using pazopanib treatment.
Identifiants
pubmed: 31427949
doi: 10.1159/000501716
pii: cro-0012-0543
pmc: PMC6696783
doi:
Types de publication
Case Reports
Langues
eng
Pagination
543-547Déclaration de conflit d'intérêts
The authors declare no conflicts of interest in association with the present study.
Références
J Clin Oncol. 2009 Aug 1;27(22):3584-90
pubmed: 19487381
Eur J Cancer. 2013 Apr;49(6):1287-96
pubmed: 23321547
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
Med Clin (Barc). 1989 Oct 14;93(11):421-3
pubmed: 2558263
Eur Urol. 2015 May;67(5):913-24
pubmed: 25616710
J Neurosurg. 1989 Jul;71(1):138-40
pubmed: 2661740
Int J Urol. 2018 Oct;25(10):901-902
pubmed: 30041283
Int J Urol. 2018 Sep;25(9):780-786
pubmed: 30066367
Int J Urol. 2019 Feb;26(2):305-306
pubmed: 30378192
Lancet Oncol. 2019 Feb;20(2):297-310
pubmed: 30658932